Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Prevention of GvHD After Allo-HSCT
NCT04935684Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Dec 2022
- Primary completion
- May 2030
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic fecal microbiota in graft-versus-host disease (GVHD), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Started Dec 2022; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04935684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935684.